Adamax — EU research guide.
Adamax is a combination research compound typically blending Semax and Selank in a single preparation, designed for concurrent nootropic, anxiolytic and BDNF-stimulating research in animal models.
What is Adamax?
Adamax is not a single molecular entity but a pre-formulated blend of Semax (ACTH 4–7 Pro-Gly-Pro) and Selank (TBCE-Lys-Glu-Asp-Gly). It is sold by EU research vendors as a convenience preparation for researchers studying concurrent BDNF upregulation (Semax) and GABAergic anxiolysis (Selank). Individual component ratios vary by vendor.
What does the research show?
The evidence base for Adamax as a combined entity is absent from peer-reviewed literature — all mechanistic data derives from individual Semax and Selank research. The theoretical rationale is synergy between the nootropic (Semax) and anxiolytic (Selank) axes, reducing stress-related cognitive interference while simultaneously upregulating neurotrophic factors.
EU legal status
As a blend of two research compounds, Adamax carries the same regulatory status as its components — not approved anywhere, available for laboratory research only. Purity verification of both components independently is recommended.
Molecular information
Pharmacokinetics
Adamax across EU suppliers
COA-verified EU vendors · Updated monthly